Summary
- Current Price
- As of today, GMAB price is $27.52, up +1.78% on
- Current Price All-Time High
- GMAB price is currently -73.33% below its historical high of $103.19 set on
- Market Cap
- GMAB current market cap is $17B, up +26.09% over the past 365 days
- PE Ratio
- GMAB current PE ratio is 17.78
- Revenue
- GMAB current annual revenue is $3.73B, up +19.53% year-over-year
- Next Earnings
- The next earnings release for GMAB is on
Profile
| Metric | Value |
|---|---|
| Full Name | Genmab A/S |
| Ticker | NASDAQ: GMAB |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Denmark |
| IPO | |
| Indexes | Not included |
| Website | genmab.com |
| Employees | 2,638 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $27.52 | |
| Price, 1D Change | +1.78% | |
| Market Cap | $17B | |
| - | ||
| PE Ratio | 17.78 | |
| Beta | 0.93 | |
| Revenue | $4B | |
| Revenue, 1Y Change | +19.53% | |
| EPS | $1.54 | |
| EPS, 1Y Change | -12.45% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 5:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | GMXAY | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $1.54 | |
| EPS Estimate | N/A | $1.15 |
| EPS Est. Change | N/A | -25.15% |
| Revenue | $3.73B | |
| Revenue Estimate | N/A | $27.60B |
| Revenue Est. Change | N/A | +639.76% |
| Current Price | $27.52 | |
| Price Target | - | $38.25 |
| Price Tgt. Change | - | +38.99% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.25 | $1.76 | +40.74% | |
| $1.91 | $1.54 | -19.41% | |
| $1.15 | N/A | -25.15% | |
| $1.72 | N/A | +11.84% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $21.29B | $3.12B | -85.34% | |
| $23.75B | $3.73B | -84.29% | |
| $27.60B | N/A | +639.76% | |
| $32.60B | N/A | +773.79% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +27.70% | |
| Price, 3Y | -31.83% | |
| Market Cap, 1Y | +26.09% | |
| Market Cap, 3Y | -35.84% | |
| Revenue, 1Y | +19.53% | |
| Revenue, 3Y | +82.10% | |
| EPS, 1Y | -12.45% | |
| EPS, 3Y | +32.05% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Date | Value |
|---|---|---|
| Current Price | $27.52 | |
| SMA 200 | $28.84 | |
| SMA 200 vs Price | +4.80% | |
| SMA 50 | $27.33 | |
| SMA 50 vs Price | -0.69% | |
| Beta | 0.93 | |
| ATR | $0.73 | |
| 14-Day RSI | 51.91 | |
| 10-Day Volatility | 28.98% | |
| 1-Year Volatility | 33.69% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $3.73B | |
| EPS | $1.54 | |
| Gross Profit | $3.42B | |
| Gross Margin | 91.69% | |
| Operating Profit | $1.25B | |
| Operating Margin | 33.60% | |
| Net Income | $965.95M | |
| Net Margin | 25.89% | |
| EBITDA | $1.33B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.93 | |
| 2.02 | ||
| 2.01 | ||
| - | ||
| 5 | ||
| 2.64 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 17.78 | |
| 4.53 | ||
| 2.89 | ||
| 15.56 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $5.85B | |
| $1.71B | ||
| $12.87B | ||
| $2.88B | ||
| $7.03B | ||
| $1.43B | ||
| Total Debt | $5.43B | |
| $291.00M | ||
| $1.07B |
Expenses
| Metric | Date | Value |
|---|---|---|
| $2.77B | ||
| $2.17B | ||
| $309.95M | ||
| $0.00 | ||
| $71.22M | ||
| $0.00 | ||
| $241.74M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| $1.19B | ||
| -$5.66B | ||
| $4.80B | ||
| Capex | $55.17M | |
| $1.13B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| HC Wainwright & Co. | → | |
| Wolfe Research | ||
| Wells Fargo | ||
| Guggenheim | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Truist Securities | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with GMAB
FAQ
What is the ticker symbol for Genmab A/S?
The ticker symbol for Genmab A/S is NASDAQ:GMAB
Does Genmab A/S pay dividends?
No, Genmab A/S does not pay dividends
What sector is Genmab A/S in?
Genmab A/S is in the Healthcare sector
What industry is Genmab A/S in?
Genmab A/S is in the Biotechnology industry
What country is Genmab A/S based in?
Genmab A/S is headquartered in Denmark
When did Genmab A/S go public?
Genmab A/S initial public offering (IPO) was on June 1, 2009
Is Genmab A/S in the S&P 500?
No, Genmab A/S is not included in the S&P 500 index
Is Genmab A/S in the NASDAQ 100?
No, Genmab A/S is not included in the NASDAQ 100 index
Is Genmab A/S in the Dow Jones?
No, Genmab A/S is not included in the Dow Jones index
When was Genmab A/S last earnings report?
Genmab A/S's most recent earnings report was on February 17, 2026
When does Genmab A/S report earnings?
The next expected earnings date for Genmab A/S is May 7, 2026
Data Sources & References
- GMAB Official Website www.genmab.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1434265/000143426526000014/0001434265-26-000014-index.htm
- GMAB Profile on Yahoo Finance finance.yahoo.com/quote/GMAB
- GMAB Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/gmab